Tumor-Agnostic AKT Inhibition: Is It Time to AKT?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 41026470.
- Also identified by DOI 10.1158/1078-0432.CCR-25-2640.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Basket trials of AKT-mutated tumors show that pan-AKT inhibitors are active in hormone receptor-positive breast cancer. There is mounting evidence for AKT inhibition in other tumor types, although small sample sizes limit evaluation of the tumor-agnostic potential for AKT inhibition. Emerging AKT1 E17K-specific molecules may improve tolerability and efficacy. See related article by McCourt et al., p. 4912.
Medical subject headings
- Proto-Oncogene Proteins c-akt
- Neoplasms
- Protein Kinase Inhibitors
- Antineoplastic Agents